Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784091 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
A Phase 3 study, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 412
- Enrollment target
NCT04784091: Completed Phase 3 study, sponsored by Tarsus Pharmaceuticals.
NCT04784091 is a Phase 3 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 412 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784091, a Phase 3 study, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 412 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
Primary Outcome
The proportion of subjects cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
Interventions
- DRUG TP-03
- DRUG TP-03 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2022-05-09 |
| Phase | Phase 3 |
What the finished NCT04784091 record still lists
NCT04784091 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which TP-03 is the first listed.
NCT04784091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04784091 about?
NCT04784091 is a clinical study titled "Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis". The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
What is the current status of trial NCT04784091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 412 participants. The study started on 2021-04-29. Estimated completion is 2022-05-09.
What interventions are being tested in trial NCT04784091?
The interventions under investigation include: TP-03 (DRUG), TP-03 Vehicle (DRUG).
Who is sponsoring clinical trial NCT04784091?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04784091's enrollment target sits among peer trials
412 906th of 2000 higher than 1,092 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI